Rb Enhances P160/SRC Coactivator-dependent Activity of Nuclear Receptors and Hormone Responsiveness
Overview
Affiliations
The retinoblastoma tumor suppressor protein (Rb) is best known as a repressor of genes involved in cell cycle progression. Rb has also been implicated in activation of transcription, in particular by nuclear receptors (NRs) and by differentiation-related transcription factors, but the relevance of this activity is unclear. We show that Rb and the related proteins p107 and p130 enhance the activity of NRs related to NGFI-B (Nur factors) through direct interactions with NGFI-B and SRC-2. Although recruitment of SRC/p160 coactivators to the NGFI-B AF1 domain is independent of Rb, its presence enhances SRC-dependent transcription. Rb potentiation of SRC coactivators is exerted on a subset (Nur factors, hepatocyte nuclear factor-4 (HNF-4), SF-1, and ER) but not all NRs. The levels of Rb-related proteins modulate hormone responsiveness of the NGFI-B-dependent pituitary proopiomelanocortin gene and HNF-4-dependent transcription during enterocyte differentiation. Increased Rb expression upon cell differentiation may promote differentiated functions, at least in part, by potentiation of NR activity.
Prophetic Granger Causality to infer gene regulatory networks.
Carlin D, Paull E, Graim K, Wong C, Bivol A, Ryabinin P PLoS One. 2017; 12(12):e0170340.
PMID: 29211761 PMC: 5718405. DOI: 10.1371/journal.pone.0170340.
Hu Z, Tang L, Zhang H, Niu J, Lou M Tumour Biol. 2015; 36(3):1429-35.
PMID: 25604140 DOI: 10.1007/s13277-014-2187-3.
Carper M, Denvir J, Boskovic G, Primerano D, Claudio P Genes Cancer. 2015; 5(11-12):420-35.
PMID: 25568667 PMC: 4279439. DOI: 10.18632/genesandcancer.43.
The p160/steroid receptor coactivator family: potent arbiters of uterine physiology and dysfunction.
Szwarc M, Kommagani R, Lessey B, Lydon J Biol Reprod. 2014; 91(5):122.
PMID: 25297546 PMC: 4434928. DOI: 10.1095/biolreprod.114.125021.
Chen Y, Schlessinger D, Nagaraja R Oncogenesis. 2013; 2:e67.
PMID: 23999628 PMC: 3816221. DOI: 10.1038/oncsis.2013.31.